RENAL PROFILE IN AMIKACIN THERAPY IN NEONATAL SEPTICEMIA

  • Uttam Kumar Roy WBUHS
  • Mrinal Pal WBUHS
  • Subinay Datta WBUHS
  • Chinmoy Ghosh WBUHS
  • Anup Kumar Das WBUHS
  • Santanu Kumar Tripathi WBUHS

Abstract

Background: Neonatal sepsis is the most common cause of neonatal deaths followed by extreme prematurity and birth asphyxia. In our hospital settings, a case of septicemia is treated with aminoglycosides (AG) combined with third generation cephalosporins. This is the standard guidelines of treatment of septicaemia.Though the duration of therapy should be 5-7days for most probable sepsis and 14 days for culture positive cases but as the cost of therapy is high, and the laboratory procedures for monitoring such duration of therapy is not possible in our hospital , short duration of 5-day therapy is practiced. Among the AGs, amikacin being extensively studied highly preferred agent because of its broadest spectrum, resistance to inactivating enzymes , least lysosomal damage, better tolerability profile and also low cost of therapy. The present piece of work aims at assessing any change in the renal profile of the babies being treated with 5-day amikacin therapy.

Materials and methods: Serum Creatinine,urea,potassium and 24 hours urinary Creatinine clearance were estimated on day 1(before initiation of therapy)and on day 3, day 5 of the septicemic neonates.These parameters were selected to assess the status of renal function of the affected neonates.

Results and conclusion :There was no significant changes in renal function with the regimen.

Downloads

Download data is not yet available.
Statistics
99 Views | 143 Downloads
How to Cite
Roy, U., Pal, M., Datta, S., Ghosh, C., Das, A., & Tripathi, S. (2013). RENAL PROFILE IN AMIKACIN THERAPY IN NEONATAL SEPTICEMIA. Journal of Drug Delivery and Therapeutics, 3(6), 57-59. https://doi.org/10.22270/jddt.v3i6.668